System and method for patients stratification through machine-learning immune checkpoint inhibitor response prediction

Abstract

A method of patient stratification between respondents and non-respondents to immuno-oncology (IO). This method, based on deep-learned features extracted owing to automatic AI-based models that have been fully-trained, goes beyond traditional radiomic standards, opening new perspective for a broader uptake of machine learning solutions in both patient care and drug development. Based on latest Machine Learning advances, the here proposed method allows predicting non-invasively a patient's tumor response to immuno-oncology therapy based treatment. The here proposed method operates not only on early stage conditions though a whole organ and lesion-agnostic analysis for prediction, but also on advanced metastatic stages through a multi-organ analysis performing a disease-agnostic and stage-agnostic prediction, potentially in accordance with response criteria defined by the RECIST 1.1 evaluation methodology.